Please ensure Javascript is enabled for purposes of website accessibility

Here's Why DexCom Is Surging Today

By Brian Feroldi - May 3, 2018 at 10:49AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Traders cheer after the company reports better-than-expected results and boosts guidance. Here's what investors need to know.

What happened

Investors in DexCom (DXCM 4.16%) are having a pleasant start to the day. Shares of the diabetes-focused medical device company jumped as much as 14% in early morning trading on Thursday after the company reported strong first-quarter results. The stock was up about 8% as of 10:22 a.m. EDT. 

So what

Here's a review of the key numbers from Dexcom's first quarter:

  • Revenue jumped 30% to $184.4 million. That was far higher than the $172.1 million in revenue that Wall Street had expected.
  • Non-GAAP net loss was $28.3 million, or $0.32 per share. That was a penny better than what analysts had projected. 
  • Cash balance at quarter end was $534 million.
Female doctor giving thumbs up.

Image source: Getty Images.

The strong start to the year caused management to raise its revenue guidance by $20 million for the full year. The company now expects revenue to land between $850 million to $860 million, which implies a growth rate of 19% at the midpoint.

Given the better-than-expected results and guidance boost, it is easy to understand why traders are feeling giddy.

Now what

Dexcom's stock has now fully recovered from the drubbing that it took in late 2017 after the FDA approved Abbott's new FreeStyle Libre System. Anyone who was smart enough to buy shares after the huge plunge has made a killing in a short period of time.

Can Dexom keep the momentum up? I'd argue that the answer is yes. The company just won FDA approval for its G6 system which boasts a number of improvements over its current system. In addition, the diabetes market is so huge that Dexcom should be able to continue growing quickly even if Abbott or Senseonics Holdings have successful product launches. 

Count me as a bull.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DexCom, Inc. Stock Quote
DexCom, Inc.
DXCM
$77.63 (4.16%) $3.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.